Vertex Pharmaceuticals Incorporated (VRTX) Q1 2015 Earnings Results

Vertex Pharmaceuticals Misses on Revenue, Stock Down 1.36%

Vertex Pharmaceuticals reported a loss per share that beat expectations, but did not provide revenue figures. The stock fell by 1.36% following the earnings report, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance without clear direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.62	N/A	+17.11%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed a cautious optimism about the future, emphasizing their commitment to pipeline development. They acknowledged current challenges but reaffirmed their dedication to patient care.

We are committed to advancing our pipeline despite the challenges.

Our focus remains on delivering innovative therapies to patients.

Vertex Pharmaceuticals Misses on Revenue, Stock Down 1.36%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Misses on Revenue, Stock Down 1.36%

Key numbers

Management commentary